Future Directions in Digital Tools and Registries for CGT LTFU Programs Future Directions in Digital Tools and Registries for CGT LTFU Programs The regulatory landscape for cell and gene therapy (CGT) products is continuously evolving, particularly concerning the requirements for long-term follow-up (LTFU) safety monitoring and post-market commitments. Regulatory, CMC, clinical, and QA leaders must understand how digital tools and registries can streamline LTFU processes while ensuring compliance with regulatory standards laid out by the US FDA. This comprehensive guide will explore the future directions in digital tools and registries for CGT LTFU programs, emphasizing the importance of safety monitoring…

Aligning Payer, HTA and Regulator Expectations for Long-Term CGT Outcomes As cell and gene therapies (CGTs) continue to evolve, regulatory, clinical, and quality assurance (QA) leaders must navigate a complex landscape that integrates payer and health technology assessment (HTA) expectations with regulatory requirements. This article serves as a comprehensive guide, detailing the processes involved in long-term follow-up (LTFU), safety monitoring, and post-market commitments that are crucial for successful integration of CGTs into healthcare systems. Understanding the Importance of Long-Term Follow-Up (LTFU) Long-term follow-up is essential in ensuring that long-term safety and efficacy of CGTs are monitored after market authorization. The…

Documentation Expectations for Post Marketing CGT Safety Commitments Introduction to Post-Marketing Safety Commitments in Cell and Gene Therapy Cell and Gene Therapy (CGT) products represent a transformative approach in modern medicine; they offer unprecedented opportunities for treating and even curing genetic disorders. However, the complexity of their mechanisms necessitates rigorous adherence to safety monitoring throughout their lifecycle, particularly post-market. The US Food and Drug Administration (FDA) establishes specific regulatory expectations for the long-term follow-up (LTFU) of patients receiving CGT products. This guide provides a detailed overview of documentation expectations for long-term follow-up safety monitoring post-market CGT commitments, ensuring compliance with…

Regulatory Interactions Around Emerging LTFU Safety Signals in CGT As cell and gene therapy (CGT) products continue to evolve, regulatory frameworks are increasingly essential to ensure their safety, efficacy, and compliance. This article aims to serve as a comprehensive tutorial on the regulatory interactions surrounding emerging long-term follow-up (LTFU) safety signals within CGT. We will discuss the significance of LTFU in the context of post-market commitments, safety monitoring, and the collection of real-world evidence. Understanding Long-Term Follow-Up in Gene Therapy Long-term follow-up (LTFU) is critical in the ongoing assessment of gene therapy products. These therapies may carry risks that are…

Using real world evidence to refine CGT risk benefit assessments over time Using Real World Evidence to Refine CGT Risk Benefit Assessments Over Time Introduction to Long-Term Follow-Up in Cell and Gene Therapy Cell and Gene Therapies (CGT) are rapidly advancing, offering transformative potential for a range of diseases. However, the unique nature of these therapies necessitates robust safety monitoring and long-term follow-up (LTFU) commitments post-approval. The integration of real-world evidence (RWE) in refining risk-benefit assessments over time is gaining critical importance within regulatory frameworks prescribed by the FDA and its counterparts in the UK and EU. As regulatory, Clinical…